At SLEEP 2026, the head of Orexin Franchise Development and Neuroscience Programs at Takeda discussed new phase 3 data of oveporexton in patients with narcolepsy type 1. [WATCH TIME: 5 minutes]
Elena Koundourakis, PhD
Advertisement
Head of Orexin Franchise Development and Neuroscience Programs at Takeda.
Articles by Elena Koundourakis, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
4
Highlighting Gaps in Testing and Diagnosis for Fragile X Syndrome: Craig A. Erickson, MD
5